Moisand Fitzgerald Tamayo LLC Purchases 19 Shares of Eli Lilly and Company (NYSE:LLY)

Moisand Fitzgerald Tamayo LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 10.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 194 shares of the company’s stock after purchasing an additional 19 shares during the quarter. Moisand Fitzgerald Tamayo LLC’s holdings in Eli Lilly and Company were worth $150,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. AMF Tjanstepension AB lifted its holdings in Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after buying an additional 176,552 shares during the period. Values Added Financial LLC lifted its holdings in Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after buying an additional 17 shares during the period. Heritage Oak Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 109.8% during the third quarter. Heritage Oak Wealth Advisors LLC now owns 860 shares of the company’s stock worth $762,000 after buying an additional 450 shares during the period. Hudock Inc. lifted its holdings in Eli Lilly and Company by 0.8% during the third quarter. Hudock Inc. now owns 2,797 shares of the company’s stock worth $2,478,000 after buying an additional 23 shares during the period. Finally, Strategic Investment Solutions Inc. IL lifted its holdings in Eli Lilly and Company by 8.3% during the third quarter. Strategic Investment Solutions Inc. IL now owns 676 shares of the company’s stock worth $599,000 after buying an additional 52 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $874.12 on Monday. The business’s 50-day moving average is $801.33 and its two-hundred day moving average is $847.66. The company has a market capitalization of $828.82 billion, a P/E ratio of 74.65, a P/E/G ratio of 1.40 and a beta of 0.42. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a share buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Bank of America reiterated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.